Summary
Edwards Lifesciences Corporation (EW) reported a strong third quarter and first nine months of 2014, driven by significant growth in Net Sales, particularly in Transcatheter Heart Valves. Net sales for the quarter rose 22.6% year-over-year to $607.4 million, and for the nine-month period increased 12.9% to $1.7 billion. This growth was propelled by the successful launches and expanded use of their next-generation transcatheter heart valves, notably the Edwards SAPIEN XT and SAPIEN 3, across the US and Europe. A significant event impacting the financial results was the settlement of patent litigation with Medtronic, which resulted in a $750.0 million upfront payment to Edwards Lifesciences in the second quarter. This substantially boosted net income, which more than doubled for the nine-month period to $701.9 million. Despite the strong sales performance, the company saw a decrease in gross profit margin due to foreign currency fluctuations and higher manufacturing costs. However, overall financial health appears robust, with ample liquidity from operations.
Financial Highlights
48 data points| Revenue | $607.40M |
| Cost of Revenue | $168.10M |
| Gross Profit | $439.30M |
| R&D Expenses | $87.60M |
| SG&A Expenses | $222.20M |
| Net Income | $94.60M |
| EPS (Basic) | $0.15 |
| EPS (Diluted) | $0.15 |
| Shares Outstanding (Basic) | 638.40M |
| Shares Outstanding (Diluted) | 650.40M |
Key Highlights
- 1Net sales increased by 22.6% to $607.4 million in Q3 2014 and by 12.9% to $1.7 billion in the first nine months of 2014, driven by strong performance in Transcatheter Heart Valves.
- 2Net income significantly increased to $94.6 million for Q3 2014 and $701.9 million for the first nine months of 2014, benefiting from a $750 million litigation settlement payment from Medtronic.
- 3The launch of new transcatheter heart valves, including the Edwards SAPIEN XT in the US and the Edwards SAPIEN 3 in Europe, was a key driver of sales growth.
- 4Gross profit margin decreased by 1.8 percentage points in Q3 and 2.6 percentage points for the nine-month period, primarily due to foreign currency exchange rate fluctuations and higher manufacturing costs.
- 5Operating expenses, specifically Selling, General & Administrative (SG&A) and Research & Development (R&D), increased to support product launches and ongoing development.
- 6The company ended the quarter with a strong liquidity position, reflected in $404.1 million in cash and cash equivalents and substantial cash flow from operations.
- 7Edwards Lifesciences repurchased $300.0 million of its common stock in the first nine months of 2014 under its authorized repurchase programs.